As an innovative new treatment option for heart failure, a unique cardiac remuscularization therapy has been invented by Dr. FUKUDA Keiichi, Founder & CEO, Professor at Keio University School of Medicine. Venture Valuation (VV) interviewed YASUI Kikuo, COO. Read the Interview Would you like to be notified about new interviews, reports and other valuable content … Continue reading Heartseed Inc., Breakthrough cell therapy for severe heart failure.
Relevant soft factors to assess startup companies Investing in early-stage companies is a risky business. Many venture capitalists have fallen victim to the consequences of a myopic attitude towards thorough risk assessments. Although the negative experiences tend to be heard first, it’s the success stories that make it all the more worthwhile. Before taking the … Continue reading How to assess start-up companies
Zurich / Singapore, July 2020 – In response to the growing need of life sciences companies for comprehensive and unbiased information on various countries and their ability to host key value drivers, KPMG, in collaboration with Venture Valuation has published its report “Site Selection for Life Sciences Companies in Asia” – the first edition. The … Continue reading Site Selection for Life Sciences Companies in Asia – New Report in Collaboration with KPMG
It is no surprise that most biotech investors are based in the US. But, do they invest exclusively in American companies? Read the report Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?
14 January 2019. Last week saw the annual J.P. Morgan Healthcare Conference held in San Francisco. Venture Valuation and Biotechgate was represented by CEO, Patrik Frei and Senior Business Development Executive Ray Carroll providing their insights into the industry announcements. It was again a busy week in San Francisco kicking off the Bio year 2019 … Continue reading J.P. Morgan Healthcare Conference Round-up by Venture Valuation / Biotechgate
Site Selection Report for Life Sciences Companies in Europe 2018 is now available in Mandarin and can be downloaded free by clicking at the link below: 生命科学企业在欧洲的选址（2018年版 The report, compiled by KPMG in association with Venture Valuation, explores the when, where and how of successful European expansion. The publication looks beyond site selection to include … Continue reading The Mandarin translation of Site Selection Report for Life Sciences Companies in Europe 2018
The new Site Selection Report for Life Sciences Companies in Europe, compiled by KPMG in association with Venture Valuation, explores the when, where and how of successful European expansion. The publication looks beyond site selection to include key work streams involved in successfully commercializing pharmaceutical products in Europe. In the 2018 edition, we identify five … Continue reading Site Selection Report for Life Sciences Companies in Europe 2018
Venture Valuation together with KPMG and EuropaBio has published its most recent report at BIO in San Francisco in June 2016. The data for the cluster analysis is from Biotechgate (www.biotechgate.com), the global Biotech and Life Sciences database. According to the report, there are three types of European countries attractive to locate key value drivers … Continue reading Life Sciences clusters in Europe Report 2016
See our exclusive 2015 analysis we did for the Genesis conference (organized by our partner Onenucleus). Download cluster report »
What makes a European Life Science site attractive to foreign investors? Together with KPMG Switzerland Venture Valuation has published this second edition statistic and extensive numbers on the European Biotechnology, Medical Technology and Pharma environment. The data is based on Biotechgate, the global Life Sciences database. Site Selection for Life Sciences Companies in Europe 2015: … Continue reading Life Sciences Clusters in Europe